International, multicenter randomized preclinical trials in translational stroke research: it's time to act
Dirnagl, Ulrich ; Fisher, Marc
Dirnagl, Ulrich
Fisher, Marc
Citations
Altmetric:
Authors
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Editorial
Publication Date
2012-06-01
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
Translational stroke research is in a crisis, and pharmaceutical companies continue to exit the field. Many reasons for the apparently insurmountable barrier between the bench and bedside in stroke drug development have been identified. It is time to act now to bridge the gap between preclinical and clinical studies of purported new therapies. We strongly believe that it is too early to abandon translational stroke research.
Source
J Cereb Blood Flow Metab. 2012 Jun;32(6):933-5. doi: 10.1038/jcbfm.2012.51. Link to article on publisher's site
Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1038/jcbfm.2012.51
Permanent Link to this Item
PubMed ID
22510602
Other Identifiers
Notes
Republished in: Stroke. 2012 Jun;43(6):1453-4. doi: 10.1161/STROKEAHA.112.653709.